Pfizer challenges Moderna Covid vaccine patents before Patent Trial and Appeal Board
Pfizer is challenging the Covid-19 vaccine patents that Moderna has accused the company of infringing before the Patent Trial and Appeal Board (PTAB), arguing that the patents are too broad and hinge on information about mRNA that was known well before the development of the vaccines.
Pfizer and BioNTech argue in two separate petitions for inter partes review filed with the PTAB Monday that Moderna is attempting to “coopt an entire field of mRNA technology.” The PTAB challenges relate to the lawsuit Moderna brought against Pfizer and BioNTech in August 2022, alleging that their vaccine Comirnaty copied Moderna’s vaccine technology, which was patented before the pandemic when Moderna was developing another mRNA vaccine for MERS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.